Wed Nov 19 10:23:28 UTC 2025: Here’s a summary of the text and a rewrite as a news article:
Summary:
The Bombay High Court has ruled against Adwin Pharma, preventing them from manufacturing and selling diabetes medication under the name “ELGIMET.” The court found the name deceptively similar to “GLIMET,” a registered trademark of Laboratories Griffon, which has been selling diabetes drugs under that name since the 1990s. The court rejected Adwin Pharma’s arguments about pricing differences and the descriptive nature of “GLIMET,” citing the potential for confusion among consumers and the importance of avoiding any confusion with medicinal products. The injunction remains in place pending the final resolution of the lawsuit.
News Article:
Bombay High Court Halts Sale of Diabetes Drug ‘ELGIMET’ Over Trademark Similarity
Mumbai, November 19, 2025 – The Bombay High Court has issued an injunction against Adwin Pharma, preventing the company from manufacturing, marketing, or selling its diabetes medication under the brand name “ELGIMET.” The ruling, delivered on November 18, 2025, found that “ELGIMET” is deceptively similar to “GLIMET,” a registered trademark of Laboratories Griffon Pvt. Ltd.
Justice Sharmila U. Deshmukh stated that the pronunciation of “ELGIMET” is likely to be misconstrued as “GI-MET,” creating phonetic similarity with “GLI-MET” and causing confusion among consumers.
Laboratories Griffon, which has been marketing diabetes drugs under the “GLIMET” brand since 1992, argued that Adwin Pharma’s use of “ELGIMET” would infringe on its established trademark. The company’s “GLIMET” and “GLIMET DS” brands have generated approximately ₹25 crore in sales in recent years.
Adwin Pharma attempted to argue that the prescription-only status of the drugs, price differences (₹7 vs ₹70 per 10 tablets), and distinct packaging negated any potential for confusion. They also claimed “GLIMET” was a descriptive term based on active pharmaceutical ingredients. However, the court rejected these arguments, emphasizing the potential for mispronunciation and imperfect recollection by consumers.
The court cited a Supreme Court precedent highlighting the need to avoid even the slightest probability of confusion regarding medicinal products. While it declined interim relief regarding passing-off claims (misrepresentation in packaging), the court’s injunction effectively halts Adwin Pharma’s sales of “ELGIMET” pending the outcome of the full lawsuit.
First Piper 